Reduction of renal uptake of 111In-DOTA-labeled and A700-labeled RAFT-RGD during integrin αvβ3 targeting using single photon emission computed tomography and optical imaging.
Identifieur interne : 000B04 ( Main/Exploration ); précédent : 000B03; suivant : 000B05Reduction of renal uptake of 111In-DOTA-labeled and A700-labeled RAFT-RGD during integrin αvβ3 targeting using single photon emission computed tomography and optical imaging.
Auteurs : RBID : pubmed:22448775English descriptors
- KwdEn :
- Animals, Cell Line, Tumor, Female, Fluorescent Dyes, HEK293 Cells, Humans, Indium (metabolism), Indium Radioisotopes (metabolism), Indium Radioisotopes (pharmacokinetics), Integrin alphaVbeta3 (metabolism), Kidney (metabolism), Metabolic Clearance Rate, Mice, Mice, Nude, Multimodal Imaging, Organometallic Compounds (metabolism), Organometallic Compounds (pharmacokinetics), Peptides, Cyclic (metabolism), Peptides, Cyclic (pharmacokinetics), Polygeline (pharmacology), Positron-Emission Tomography, Tissue Distribution, Tomography, X-Ray Computed.
- MESH :
- chemical , metabolism : Indium, Indium Radioisotopes, Integrin alphaVbeta3, Organometallic Compounds, Peptides, Cyclic.
- chemical , pharmacokinetics : Indium Radioisotopes, Organometallic Compounds, Peptides, Cyclic.
- chemical , pharmacology : Polygeline.
- chemical : Fluorescent Dyes.
- metabolism : Kidney.
- Animals, Cell Line, Tumor, Female, HEK293 Cells, Humans, Metabolic Clearance Rate, Mice, Mice, Nude, Multimodal Imaging, Positron-Emission Tomography, Tissue Distribution, Tomography, X-Ray Computed.
Abstract
Integrin α(v)β(3) expression is upregulated during tumor growth and invasion in newly formed endothelial cells in tumor neovasculature and in some tumor cells. A tetrameric RGD-based peptide, regioselectively addressable functionalized template-(cyclo-[RGDfK])4 (RAFT-RGD), specifically targets integrin α(v)β(3) in vitro and in vivo. When labeled with indium-111, the RAFT-RGD is partially reabsorbed and trapped in the kidneys, limiting its use for further internal targeted radiotherapy and imaging investigations. We studied the effect of Gelofusine on RAFT-RGD renal retention in tumor-bearing mice. Mice were imaged using single photon emission computed tomography and optical imaging 1 and 24 h following tracer injection. Distribution of RAFT-RGD was further investigated by tissue removal and direct counting of the tracer. Kidney sections were analyzed by confocal microscopy. Gelofusine significantly induced a >50% reduction of the renal reabsorption of (111)In-DOTA-RAFT-RGD and A700-RAFT-RGD, without affecting tumor uptake. Injection of Gelofusine significantly reduced the renal retention of labeled RAFT-RGD, while increasing the tumor over healthy tissue ratio. These results will lead to the development of future therapeutic approaches.
DOI: 10.1111/j.1349-7006.2012.02286.x
PubMed: 22448775
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Reduction of renal uptake of 111In-DOTA-labeled and A700-labeled RAFT-RGD during integrin αvβ3 targeting using single photon emission computed tomography and optical imaging.</title><author><name sortKey="Briat, Arnaud" uniqKey="Briat A">Arnaud Briat</name><affiliation wicri:level="1"><nlm:affiliation>INSERM U877, Radiopharmaceutiques Biocliniques, Grenoble, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM U877, Radiopharmaceutiques Biocliniques, Grenoble</wicri:regionArea><placeName><region type="région">Rhône-Alpes</region><settlement type="city">Grenoble</settlement></placeName></affiliation></author><author><name sortKey="Wenk, Christiane H F" uniqKey="Wenk C">Christiane H F Wenk</name></author><author><name sortKey="Ahmadi, Mitra" uniqKey="Ahmadi M">Mitra Ahmadi</name></author><author><name sortKey="Claron, Michael" uniqKey="Claron M">Michael Claron</name></author><author><name sortKey="Boturyn, Didier" uniqKey="Boturyn D">Didier Boturyn</name></author><author><name sortKey="Josserand, Veronique" uniqKey="Josserand V">Véronique Josserand</name></author><author><name sortKey="Dumy, Pascal" uniqKey="Dumy P">Pascal Dumy</name></author><author><name sortKey="Fagret, Daniel" uniqKey="Fagret D">Daniel Fagret</name></author><author><name sortKey="Coll, Jean Luc" uniqKey="Coll J">Jean-Luc Coll</name></author><author><name sortKey="Ghezzi, Catherine" uniqKey="Ghezzi C">Catherine Ghezzi</name></author><author><name sortKey="Sancey, Lucie" uniqKey="Sancey L">Lucie Sancey</name></author><author><name sortKey="Vuillez, Jean Philippe" uniqKey="Vuillez J">Jean-Philippe Vuillez</name></author></titleStmt><publicationStmt><date when="2012">2012</date><idno type="doi">10.1111/j.1349-7006.2012.02286.x</idno><idno type="RBID">pubmed:22448775</idno><idno type="pmid">22448775</idno><idno type="wicri:Area/Main/Corpus">000E10</idno><idno type="wicri:Area/Main/Curation">000E10</idno><idno type="wicri:Area/Main/Exploration">000B04</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Cell Line, Tumor</term><term>Female</term><term>Fluorescent Dyes</term><term>HEK293 Cells</term><term>Humans</term><term>Indium (metabolism)</term><term>Indium Radioisotopes (metabolism)</term><term>Indium Radioisotopes (pharmacokinetics)</term><term>Integrin alphaVbeta3 (metabolism)</term><term>Kidney (metabolism)</term><term>Metabolic Clearance Rate</term><term>Mice</term><term>Mice, Nude</term><term>Multimodal Imaging</term><term>Organometallic Compounds (metabolism)</term><term>Organometallic Compounds (pharmacokinetics)</term><term>Peptides, Cyclic (metabolism)</term><term>Peptides, Cyclic (pharmacokinetics)</term><term>Polygeline (pharmacology)</term><term>Positron-Emission Tomography</term><term>Tissue Distribution</term><term>Tomography, X-Ray Computed</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Indium</term><term>Indium Radioisotopes</term><term>Integrin alphaVbeta3</term><term>Organometallic Compounds</term><term>Peptides, Cyclic</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Indium Radioisotopes</term><term>Organometallic Compounds</term><term>Peptides, Cyclic</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Polygeline</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Fluorescent Dyes</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Kidney</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Cell Line, Tumor</term><term>Female</term><term>HEK293 Cells</term><term>Humans</term><term>Metabolic Clearance Rate</term><term>Mice</term><term>Mice, Nude</term><term>Multimodal Imaging</term><term>Positron-Emission Tomography</term><term>Tissue Distribution</term><term>Tomography, X-Ray Computed</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Integrin α(v)β(3) expression is upregulated during tumor growth and invasion in newly formed endothelial cells in tumor neovasculature and in some tumor cells. A tetrameric RGD-based peptide, regioselectively addressable functionalized template-(cyclo-[RGDfK])4 (RAFT-RGD), specifically targets integrin α(v)β(3) in vitro and in vivo. When labeled with indium-111, the RAFT-RGD is partially reabsorbed and trapped in the kidneys, limiting its use for further internal targeted radiotherapy and imaging investigations. We studied the effect of Gelofusine on RAFT-RGD renal retention in tumor-bearing mice. Mice were imaged using single photon emission computed tomography and optical imaging 1 and 24 h following tracer injection. Distribution of RAFT-RGD was further investigated by tissue removal and direct counting of the tracer. Kidney sections were analyzed by confocal microscopy. Gelofusine significantly induced a >50% reduction of the renal reabsorption of (111)In-DOTA-RAFT-RGD and A700-RAFT-RGD, without affecting tumor uptake. Injection of Gelofusine significantly reduced the renal retention of labeled RAFT-RGD, while increasing the tumor over healthy tissue ratio. These results will lead to the development of future therapeutic approaches.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">22448775</PMID><DateCreated><Year>2012</Year><Month>06</Month><Day>01</Day></DateCreated><DateCompleted><Year>2012</Year><Month>08</Month><Day>27</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1349-7006</ISSN><JournalIssue CitedMedium="Internet"><Volume>103</Volume><Issue>6</Issue><PubDate><Year>2012</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Cancer science</Title><ISOAbbreviation>Cancer Sci.</ISOAbbreviation></Journal><ArticleTitle>Reduction of renal uptake of 111In-DOTA-labeled and A700-labeled RAFT-RGD during integrin αvβ3 targeting using single photon emission computed tomography and optical imaging.</ArticleTitle><Pagination><MedlinePgn>1105-10</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1349-7006.2012.02286.x</ELocationID><Abstract><AbstractText>Integrin α(v)β(3) expression is upregulated during tumor growth and invasion in newly formed endothelial cells in tumor neovasculature and in some tumor cells. A tetrameric RGD-based peptide, regioselectively addressable functionalized template-(cyclo-[RGDfK])4 (RAFT-RGD), specifically targets integrin α(v)β(3) in vitro and in vivo. When labeled with indium-111, the RAFT-RGD is partially reabsorbed and trapped in the kidneys, limiting its use for further internal targeted radiotherapy and imaging investigations. We studied the effect of Gelofusine on RAFT-RGD renal retention in tumor-bearing mice. Mice were imaged using single photon emission computed tomography and optical imaging 1 and 24 h following tracer injection. Distribution of RAFT-RGD was further investigated by tissue removal and direct counting of the tracer. Kidney sections were analyzed by confocal microscopy. Gelofusine significantly induced a >50% reduction of the renal reabsorption of (111)In-DOTA-RAFT-RGD and A700-RAFT-RGD, without affecting tumor uptake. Injection of Gelofusine significantly reduced the renal retention of labeled RAFT-RGD, while increasing the tumor over healthy tissue ratio. These results will lead to the development of future therapeutic approaches.</AbstractText><CopyrightInformation>© 2012 Japanese Cancer Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Briat</LastName><ForeName>Arnaud</ForeName><Initials>A</Initials><Affiliation>INSERM U877, Radiopharmaceutiques Biocliniques, Grenoble, France.</Affiliation></Author><Author ValidYN="Y"><LastName>Wenk</LastName><ForeName>Christiane H F</ForeName><Initials>CH</Initials></Author><Author ValidYN="Y"><LastName>Ahmadi</LastName><ForeName>Mitra</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Claron</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Boturyn</LastName><ForeName>Didier</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Josserand</LastName><ForeName>Véronique</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Dumy</LastName><ForeName>Pascal</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Fagret</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Coll</LastName><ForeName>Jean-Luc</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Ghezzi</LastName><ForeName>Catherine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Sancey</LastName><ForeName>Lucie</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Vuillez</LastName><ForeName>Jean-Philippe</ForeName><Initials>JP</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType>Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>04</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Cancer Sci</MedlineTA><NlmUniqueID>101168776</NlmUniqueID><ISSNLinking>1347-9032</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>111In-DOTA-cyclo(arginyl-glycyl-aspartyl-phenylalanyl-lysyl)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Fluorescent Dyes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Indium Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Integrin alphaVbeta3</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Organometallic Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Peptides, Cyclic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>RAFT-RGD</NameOfSubstance></Chemical><Chemical><RegistryNumber>045A6V3VFX</RegistryNumber><NameOfSubstance>Indium</NameOfSubstance></Chemical><Chemical><RegistryNumber>9015-56-9</RegistryNumber><NameOfSubstance>Polygeline</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Fluorescent Dyes</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Indium</DescriptorName><QualifierName MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Indium Radioisotopes</DescriptorName><QualifierName MajorTopicYN="N">metabolism</QualifierName><QualifierName MajorTopicYN="Y">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Integrin alphaVbeta3</DescriptorName><QualifierName MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Kidney</DescriptorName><QualifierName MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Metabolic Clearance Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Mice, Nude</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Multimodal Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Organometallic Compounds</DescriptorName><QualifierName MajorTopicYN="N">metabolism</QualifierName><QualifierName MajorTopicYN="Y">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Peptides, Cyclic</DescriptorName><QualifierName MajorTopicYN="N">metabolism</QualifierName><QualifierName MajorTopicYN="Y">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Polygeline</DescriptorName><QualifierName MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Tissue Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Tomography, X-Ray Computed</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>11</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2012</Year><Month>3</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>3</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="aheadofprint"><Year>2012</Year><Month>4</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>8</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1111/j.1349-7006.2012.02286.x</ArticleId><ArticleId IdType="pubmed">22448775</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B04 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000B04 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:22448775
|texte= Reduction of renal uptake of 111In-DOTA-labeled and A700-labeled RAFT-RGD during integrin αvβ3 targeting using single photon emission computed tomography and optical imaging.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:22448775" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a IndiumV2
| This area was generated with Dilib version V0.5.76. |  |